Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cooperative Behavior | 2 | 2015 | 27 | 0.680 |
Why?
|
| Myocardial Infarction | 2 | 2012 | 20 | 0.680 |
Why?
|
| Air Pollution | 3 | 2012 | 5 | 0.670 |
Why?
|
| HIV Infections | 2 | 2015 | 190 | 0.640 |
Why?
|
| Air Pollutants | 2 | 2012 | 23 | 0.620 |
Why?
|
| Stress, Psychological | 2 | 2015 | 137 | 0.610 |
Why?
|
| Humans | 12 | 2015 | 7258 | 0.430 |
Why?
|
| Likelihood Functions | 1 | 2015 | 26 | 0.420 |
Why?
|
| Self Report | 1 | 2015 | 56 | 0.420 |
Why?
|
| Particulate Matter | 2 | 2012 | 3 | 0.410 |
Why?
|
| Respiratory Tract Diseases | 2 | 2012 | 4 | 0.410 |
Why?
|
| Cardiovascular Diseases | 2 | 2012 | 36 | 0.400 |
Why?
|
| United States | 5 | 2015 | 441 | 0.370 |
Why?
|
| Zidovudine | 1 | 2013 | 1 | 0.370 |
Why?
|
| Nevirapine | 1 | 2013 | 1 | 0.370 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2013 | 4 | 0.360 |
Why?
|
| Female | 8 | 2015 | 4162 | 0.360 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 13 | 0.360 |
Why?
|
| Eyeglasses | 1 | 2013 | 54 | 0.360 |
Why?
|
| HIV-1 | 1 | 2013 | 43 | 0.360 |
Why?
|
| Visual Fields | 1 | 2013 | 125 | 0.350 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 5 | 0.350 |
Why?
|
| Sulfates | 1 | 2012 | 7 | 0.340 |
Why?
|
| Nitrates | 1 | 2012 | 10 | 0.340 |
Why?
|
| Myopia | 1 | 2013 | 107 | 0.340 |
Why?
|
| Carbon | 1 | 2012 | 30 | 0.330 |
Why?
|
| Adult | 6 | 2015 | 2487 | 0.320 |
Why?
|
| Vulvar Neoplasms | 1 | 2011 | 1 | 0.310 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 20 | 0.310 |
Why?
|
| Commerce | 1 | 2010 | 9 | 0.290 |
Why?
|
| Environment | 1 | 2010 | 26 | 0.290 |
Why?
|
| Interferon-alpha | 1 | 2009 | 3 | 0.280 |
Why?
|
| Antiviral Agents | 1 | 2009 | 12 | 0.280 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 25 | 0.270 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 27 | 0.270 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 65 | 0.260 |
Why?
|
| Nursing Staff, Hospital | 1 | 2008 | 6 | 0.260 |
Why?
|
| Organizational Culture | 1 | 2008 | 19 | 0.260 |
Why?
|
| Workload | 1 | 2008 | 16 | 0.260 |
Why?
|
| Data Collection | 1 | 2008 | 50 | 0.260 |
Why?
|
| Smoking | 1 | 2012 | 303 | 0.260 |
Why?
|
| Regression Analysis | 3 | 2015 | 178 | 0.250 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 33 | 0.250 |
Why?
|
| Young Adult | 3 | 2015 | 690 | 0.240 |
Why?
|
| Cognition | 1 | 2009 | 179 | 0.240 |
Why?
|
| Risk Assessment | 3 | 2012 | 97 | 0.230 |
Why?
|
| Aged, 80 and over | 3 | 2012 | 397 | 0.220 |
Why?
|
| Male | 5 | 2015 | 4565 | 0.220 |
Why?
|
| Middle Aged | 3 | 2015 | 1841 | 0.200 |
Why?
|
| Pregnancy | 2 | 2015 | 158 | 0.190 |
Why?
|
| Aged | 3 | 2012 | 1145 | 0.190 |
Why?
|
| Poisson Distribution | 2 | 2012 | 7 | 0.170 |
Why?
|
| Medicare | 2 | 2012 | 18 | 0.170 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 154 | 0.170 |
Why?
|
| Models, Statistical | 2 | 2012 | 120 | 0.160 |
Why?
|
| Workplace | 1 | 2015 | 11 | 0.110 |
Why?
|
| Urban Population | 1 | 2015 | 21 | 0.110 |
Why?
|
| Schools | 1 | 2015 | 25 | 0.110 |
Why?
|
| Botswana | 1 | 2015 | 1 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2015 | 12 | 0.110 |
Why?
|
| Prenatal Care | 1 | 2015 | 9 | 0.110 |
Why?
|
| Prevalence | 1 | 2015 | 129 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2013 | 4 | 0.090 |
Why?
|
| HIV Antibodies | 1 | 2013 | 14 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 30 | 0.090 |
Why?
|
| Disease Progression | 1 | 2013 | 90 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 42 | 0.090 |
Why?
|
| Local Government | 1 | 2012 | 3 | 0.090 |
Why?
|
| Government Regulation | 1 | 2012 | 6 | 0.090 |
Why?
|
| Patient Admission | 1 | 2012 | 8 | 0.090 |
Why?
|
| Refraction, Ocular | 1 | 2013 | 128 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 85 | 0.090 |
Why?
|
| Uncertainty | 1 | 2012 | 9 | 0.080 |
Why?
|
| Hospitalization | 1 | 2012 | 39 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 99 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2012 | 175 | 0.080 |
Why?
|
| Incidence | 1 | 2012 | 71 | 0.080 |
Why?
|
| Adolescent | 1 | 2015 | 1090 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2012 | 340 | 0.080 |
Why?
|
| Premenopause | 1 | 2011 | 2 | 0.080 |
Why?
|
| Postmenopause | 1 | 2011 | 9 | 0.080 |
Why?
|
| Child | 1 | 2013 | 880 | 0.080 |
Why?
|
| United States Environmental Protection Agency | 1 | 2010 | 2 | 0.070 |
Why?
|
| Environmental Exposure | 1 | 2010 | 11 | 0.070 |
Why?
|
| Greenhouse Effect | 1 | 2010 | 1 | 0.070 |
Why?
|
| Efficiency | 1 | 2010 | 2 | 0.070 |
Why?
|
| Climate Change | 1 | 2010 | 3 | 0.070 |
Why?
|
| Public Health | 1 | 2010 | 15 | 0.070 |
Why?
|
| Time Factors | 1 | 2012 | 709 | 0.070 |
Why?
|
| Drug Carriers | 1 | 2009 | 14 | 0.070 |
Why?
|
| Survival Rate | 1 | 2009 | 49 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 90 | 0.070 |
Why?
|
| Prognosis | 1 | 2009 | 146 | 0.070 |
Why?
|
| Education, Nursing, Diploma Programs | 1 | 2008 | 1 | 0.070 |
Why?
|
| Role | 1 | 2008 | 1 | 0.070 |
Why?
|
| Conflict (Psychology) | 1 | 2008 | 4 | 0.070 |
Why?
|
| Risk Factors | 1 | 2010 | 354 | 0.070 |
Why?
|
| Southwestern United States | 1 | 2008 | 7 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2008 | 17 | 0.070 |
Why?
|
| Intention | 1 | 2008 | 24 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2009 | 397 | 0.060 |
Why?
|
| Neuropsychological Tests | 1 | 2009 | 367 | 0.060 |
Why?
|